Marker X CO., LTD.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
Marker X provides advanced AI proteomics services that combine artificial intelligence with cutting-edge protein analysis technology to promote early disease detection and biomedical innovation. Their core offerings include AI Proteomics Early Cancer Screening, which analyzes blood protein biomarkers to identify cancers such as colorectal, lung, esophageal, and breast cancer at an early stage, and Proteomics Research Services, supporting scientific and clinical studies with high-resolution mass spectrometry and bioinformatics analysis. With fast testing, accurate results, and personalized health reports, Marker X aims to make precision health screening accessible, reliable, and preventive for everyone.
Founded Year
2020
Unified Business No.
82941917
Status
Active
Number of Employees
0
Total Paid-in
Capital
110,814,464 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
At Marker X, we are dedicated to providing the most accurate and effective multi-cancer early detection (MCED) method. Through the use of cutting-edge proteomic analysis, and artificial intelligence, we are able to detect cancer at its earliest stages, giving patients the best chance for pursuing their lives and creating value to the world.
